In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
Pfizer (NYSE:PFE) will pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that ... now-discontinued heartburn drug Zantac. The drugmaker has agreed to pay between $200M and $250M ...
Pfizer (NYSE:PFE) has reportedly agreed to pay up to $250M to settle ... which sold Zantac between 1998 and 2006, said it continues to “vigorously defend against Zantac lawsuits, which it ...
Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated with its now-discontinued heartburn drug Zantac, according to people familiar with the deal.
Pfizer has agreed to pay between $200m to $250m to settle more than 10,000 US lawsuits over cancer risks associated with Zantac, Financial Times reports, citing two unidentified people briefed on the ...
opens new tab will pay up to $250 million to settle more than 10,000 U.S. lawsuits ... added. Pfizer did not immediately reply to Reuters' request for comment. First approved in 1983, Zantac ...
We all want a crystal ball, something that will let us peer a few months into the future and know how the markets are going to shake out. Of course, that won’t happen – but it won’t stop ...
(Reuters) -Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on ...
(Reuters) - Pfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the United States over cancer risks associated with its now-discontinued heartburn drug Zantac, ...
GSK’s shares fell sharply following a judge's decision to allow more than 70,000 lawsuits to proceed, alleging it’s Zantac ...